New UK Market Surveillance Levy Could Cost Medtech Companies Millions Each Year
This article was originally published in Clinica
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) wants to charge an annual fee to manufacturers to pay for its market surveillance activities, but is expected to issue a 12-week public consultation first. The exact level of fee is not yet known but is expected to be in the region of 0.12% of turnover, Mike Kreuzer, regulatory director of the Association of British Healthcare Industries told delegates at the Bristows/ABHI medical device meeting in London on April 21.
You may also be interested in...
The UK health technology assessment body, NICE, has received its first reactions from a medtech industry association to proposals to raise fees from its program of pharma guidance. If, when or how quickly the medtech sector is fully impacted is a matter of concern across the SME-based industry.
Those marketing products covered under the EU’s MDR and IVD Regulations have plenty of reading this month to help them prepare. More details have also emerged about the UK’s regulatory future.
Where are the biggest challenges for notified bodies and manufacturers now there is some experience with the MDR, and can the sector manage the new regulatory requirements successfully?